rain_logo.png
Rain Therapeutics to Present Data on Tarloxotinib at the American Association for Cancer Research (AACR) Annual Meeting 2019
February 28, 2019 08:00 ET | Rain Therapeutics
NEWARK, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients...
rain_logo.png
Rain Therapeutics Announces Presentations on Tarloxotinib at the 30th EORTC-NCI-AACR Symposium
November 06, 2018 08:00 ET | Rain Therapeutics
FREMONT, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...
rain_logo.png
Lori Kunkel, M.D. Joins the Rain Therapeutics Scientific Advisory Board (SAB)
October 01, 2018 08:00 ET | Rain Therapeutics
FREMONT, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...
rain_logo.png
Rain Therapeutics Announces Collaborator Presentations on Tarloxotinib at Two Upcoming Conferences
August 22, 2018 16:01 ET | Rain Therapeutics
FREMONT, Calif., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...
rain_logo.png
Rain Therapeutics Announces Collaborator Presentations on Tarloxotinib at the 5th International Conference on Tumor Microenvironment and Cellular Stress
June 05, 2018 08:01 ET | Rain Therapeutics
FREMONT, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...
rain_logo.png
Rain Therapeutics Closes $18 Million Series A Financing
May 21, 2018 08:00 ET | Rain Therapeutics
FREMONT, Calif., May 21, 2018 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients...